Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication

Plain Language SummaryWhat is this summary about?This is a summary of an article that describes the results of the RAISE clinical study.Zilucoplan is being investigated as a treatment for an autoimmune disease called generalised myasthenia gravis. Conventional treatments for myasthenia gravis do not always work well and often have side effects that can limit their use. There is a need for new and improved treatments. The RAISE clinical study looked at whether subcutaneous (under the skin) zilucoplan injections taken once per day were better than a placebo at treating symptoms of generalised myasthenia gravis.What were the results?People who took zilucoplan for 12 weeks had a rapid (after 1 week) and clinically meaningful improvement of symptoms of generalised myasthenia gravis, compared with people who took placebo. The most common side effects during the study were mild bruising at the site of injection and headache.What do the results mean?The results mean that zilucoplan was an effective treatment for myasthenia gravis and had favourable safety results. The efficacy and safety of zilucoplan when taken for longer than 12 weeks are being assessed in an extension of this study.How to say…Zilucoplan: Zi-LOO-co-PLAN or Zy-LOO-co-PLANMyasthenia gravis: My-as-THEEN-ee-a GRAH-vissPlacebo: Pluh-SEE-bohAcetylcholine: A-SIT-ile-KOH-leenSide effects: Unintended effects while taking a medication.Placebo: A medicine that looks and feels (and, if relevant, tastes) the same as the active treatment, but contains no active ingredients. A placebo may be used in clinical studies to ensure patients and doctors are not biased when completing assessments of symptoms, by making sure they remain unaware of whether the patient is on treatment or not.Clinically meaningful improvement: For myasthenia gravis, an improvement of 2 or more points in the MG-ADL score and an improvement of 3 or more in MGC and QMG scores is considered to be clinically meaningful. This level of improvement is likely to be large enough to be relevant to patients.Efficacy: The ability of a drug to produce a desired effect.Extension: An additional period after the observational period during which patients can continue to take the medication if they wish. The extension period helps to understand the safety and efficacy of a treatment over a longer period of time than the initial clinical trial period.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article hereTrial registration: ClinicalTrials.gov identifier: NCT04115293.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.